IVVD compared with MNPR: revenue, margins and what each company keeps, and the suppliers and customers both name

IVVDInvivyd, Inc.

Mkt capRevenueRevenue

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

Compare

IVVDInvivyd, Inc.

MNPRMonopar Therapeutics

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IVVD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±48.9%▲+5.13%×0.10

MNPR

Reportimpliedrealized× implied

Q2 FY26—▲+0.38%—

May 14 '26—▼−0.73%—

Q1 FY26

= impliedIVVD realized, solidMNPR realized, hatchedOne scale, both sides: full bar = 49%× = |realized| ÷ impliedSource: market data

—

▼−0.84%

—

Q3 FY25—▲+5.36%—

IVVDInvivyd, Inc.

0.59· pre 0.62

Mkt cap$171.5MRevenue$14MQ2 FY26Revenue$53MFY25

MNPRMonopar Therapeutics

69.99· pre 69.99· delayed

Pre-marketSep 2 '83

Mkt cap$472.0MRevenue—Revenue—

Compare

Pre-marketSep 2 '83

IVVDInvivyd, Inc.

MNPRMonopar Therapeutics

0.59pre 0.62

Price

69.99pre 69.99delayed

$171.5M

Mkt cap

$472.0M

Q2 FY26$14M

Revenue

—

FY25$53M

Revenue

—

IVVD0.59vsMNPR69.99Pre-marketSep 2 '83